| All patients | IgM anti-CMV(+) patients | IgM anti-CMV(-) IgG anti-CMV(+) patients |
---|---|---|---|
n | 59 | 20a | 39 |
Age (years) | 36.7 ± 14.1 (13 to 72) | 34.3 ± 15.1 (14 to 72) | 37.9 ± 13.6 (13 to 64) |
Sex (female/male) | 56/3 | 18/2 | 38/1 |
Disease status | Â | Â | Â |
   Disease duration (years) | 7.4 ± 6.4 (0.1 to 36) | 9.4 ± 8.0 (2 to 36) | 6.5 ± 5.3 (0.1 to 23) |
   Age at diagnosis (years) | 29.2 ± 12.1 (7 to 57) | 24.9 ± 10.9* (7 to 57) | 31.5 ± 12.3* (12 to 57) |
Clinical assessment | Â | Â | Â |
   Mexican SLEDAI | 2.88 ± 2.97 (0.0 to 12) | 3.30 ± 3.26 (0.0 to 10) | 2.67 ± 2.83 (0.0 to 12) |
   SLICC | 0.76 ± 1.75 (0.0 to 12) | 1.11 ± 2.75 (0.0 to 12) | 0.59 ± 0.97 (0.0 to 3) |
Laboratory data | Â | Â | Â |
   Rheumatoid factor (IU/ml) | 18.2 ± 20.9 (2 to 108) | 21.3 ± 29.0 (2 to 108) | 16.7 ± 15.5 (3 to 60) |
   Soluble IL-10 (pg/ml) | 27.9 ± 54.8 (9.31 to 422) | 39.4 ± 90.5 (11.7 to 422) | 22.0 ± 19.4 (9.3 to 126.7) |
   IgG CMV (U) | 233.7 ± 46.3 (3.5 to 250) | 233.6 ± 55.3 (3.5 to 250) | 233.8 ± 41.8 (70 to 250) |
   White blood cells (/μl) | 5,782 ± 2,008 (2,870 to 12,100) | 5,413 ± 1,713 (2,900 to 8,700) | 5,962 ± 2,135 (2,870 to 12,100) |
   Lymphocyte (/μl) | 1493 ± 688 (154 to 3,400) | 1450 ± 676 (154 to 2,890) | 1515 ± 702 (269 to 3,400) |
   Platelet (× 103/μl) | 273.8 ± 63.9 (137 to 445) | 262.8 ± 81.7 (137 to 445) | 279.2 ± 53.7 (167 to 385) |
Treatment | Â | Â | Â |
   Azathioprine (%) | 59 | 47 | 64 |
   Methotrexate (%) | 21 | 16 | 23 |
   Cyclophosphamide (%) | 5 | 5 | 5 |
   Immunosuppressive therapyb (%) | 79 | 63 | 87 |
   Chloroquine (%) | 52 | 53 | 51 |
   On steroid (%) | 57 | 68 | 51 |
   Steroid dose (prednisone mg/day) | 4.7 ± 6.1 | 5.9 ± 5.9 | 4.1 ± 6.2 |
   Prednisone ≥ 10 mg/day (%) | 17 | 26 | 13 |